Switching from Dulaglutide to Tirzepatide Shows Superior Efficacy in Type 2 Diabetes

Type 2 Diabetes (T2D) is a progressive metabolic disorder characterized by high blood glucose, often managed with GLP-1 receptor agonists like dulaglutide. While effective, some patients may require more potent therapies to achieve optimal glycemic control and weight management. Newer dual agonists, such as tirzepatide (a GLP-1/GIP receptor agonist), have demonstrated superior efficacy in head-to-head trials. This study specifically addresses the knowledge gap regarding the safety and efficacy of switching patients from dulaglutide to tirzepatide across various clinically relevant baseline characteristics.

The subgroup analysis consistently demonstrated that switching from dulaglutide to tirzepatide led to significantly greater improvements in both glycemic control and body weight reduction across all examined baseline characteristics. Participants who switched to tirzepatide experienced an average HbA1c reduction of ~2.0% from baseline, compared to a modest ~0.5% reduction in those continuing dulaglutide (p<0.001). The most important finding was that tirzepatide achieved superior HbA1c reductions and weight loss compared to dulaglutide, regardless of baseline age, BMI, or diabetes duration, highlighting its broad applicability. Weight reduction was also substantially higher in the tirzepatide groups, with an average loss of ~7 kg (or ~7% of body weight) versus an average gain of ~1 kg in the dulaglutide group (p<0.001). The safety profile was generally consistent with known GLP-1 receptor agonist effects, with gastrointestinal adverse events (e.g., nausea, diarrhea) being the most common, reported in ~30-40% of tirzepatide patients, but rarely leading to treatment discontinuation.